(ASH) Ashland Global Holdings - Overview
Stock: Additives, Ingredients, Binders, Coatings, Emulsifiers
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.96% |
| Yield on Cost 5y | 2.62% |
| Yield CAGR 5y | 8.86% |
| Payout Consistency | 93.5% |
| Payout Ratio | 49.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.0% |
| Relative Tail Risk | -11.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -18.43 |
| Character TTM | |
|---|---|
| Beta | 1.092 |
| Beta Downside | 1.189 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.78% |
| CAGR/Max DD | -0.26 |
Description: ASH Ashland Global Holdings January 14, 2026
Ashland Inc. (NYSE:ASH) manufactures additives and specialty ingredients for a global customer base across North and Latin America, Europe, and Asia-Pacific. The company operates four segments: Life Sciences (pharmaceutical and nutrition solutions, agricultural chemicals, diagnostics, fine chemicals), Personal Care (nature-derived, biodegradable ingredients for oral care and household products), Specialty Additives (rheology modifiers, surfactants, advanced ceramics for catalytic converters, capacitors, solar cells, and textile printing), and Intermediates (1,4-butanediol and related solvents such as N-methyl-2-pyrrolidone). Its product portfolio serves end-markets ranging from architectural coatings and construction to food & beverage, energy, and pharma.
In FY 2023 Ashland reported revenue of roughly $2.5 billion, with an adjusted EBITDA margin of ~12%, reflecting steady pricing power in high-margin specialty chemicals. The segment most sensitive to macro trends is Specialty Additives, where demand is being driven by the global shift toward low-carbon, recyclable materials and the growth of electric-vehicle catalytic converter production. Additionally, the Life Sciences segment benefits from a 6-year compound annual growth rate (CAGR) of ~5% in the global pharmaceutical excipients market, supported by rising generic drug pipelines and increased oral-solid-dose formulations.
For a deeper, data-rich assessment of Ashland’s valuation dynamics, you may find ValueRay’s analytical toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -691.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 5.02 > 1.0 |
| NWC/Revenue: 43.63% < 20% (prev 31.48%; Δ 12.16% < -1%) |
| CFO/TA 0.08 > 3% & CFO 365.0m > Net Income -691.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.2m) vs 12m ago -2.18% < -2% |
| Gross Margin: 28.68% > 18% (prev 0.31%; Δ 2837 % > 0.5%) |
| Asset Turnover: 37.05% > 50% (prev 39.11%; Δ -2.07% > 0%) |
| Interest Coverage Ratio: -8.78 > 6 (EBITDA TTM -309.0m / Interest Expense TTM 63.0m) |
Altman Z'' 2.92
| A: 0.17 (Total Current Assets 1.15b - Total Current Liabilities 366.0m) / Total Assets 4.52b |
| B: 0.50 (Retained Earnings 2.27b / Total Assets 4.52b) |
| C: -0.11 (EBIT TTM -553.0m / Avg Total Assets 4.88b) |
| D: 0.86 (Book Value of Equity 2.27b / Total Liabilities 2.64b) |
| Altman-Z'' Score: 2.92 = A |
Beneish M -3.10
| DSRI: 1.32 (Receivables 190.0m/163.0m, Revenue 1.81b/2.05b) |
| GMI: 1.08 (GM 28.68% / 30.89%) |
| AQI: 0.85 (AQ_t 0.46 / AQ_t-1 0.54) |
| SGI: 0.88 (Revenue 1.81b / 2.05b) |
| TATA: -0.23 (NI -691.0m - CFO 365.0m) / TA 4.52b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of ASH shares?
Over the past week, the price has changed by +1.10%, over one month by -0.16%, over three months by +25.74% and over the past year by +0.21%.
Is ASH a buy, sell or hold?
- StrongBuy: 6
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ASH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 66.8 | 7.3% |
| Analysts Target Price | 66.8 | 7.3% |
| ValueRay Target Price | 66.3 | 6.5% |
ASH Fundamental Data Overview February 08, 2026
P/S = 1.6267
P/B = 1.5383
P/EG = -1.36
Revenue TTM = 1.81b USD
EBIT TTM = -553.0m USD
EBITDA TTM = -309.0m USD
Long Term Debt = 1.39b USD (from longTermDebt, last quarter)
Short Term Debt = 19.0m USD (from shortTermDebt, last quarter)
Debt = 1.49b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.19b USD (from netDebt column, last quarter)
Enterprise Value = 4.12b USD (2.94b + Debt 1.49b - CCE 304.0m)
Interest Coverage Ratio = -8.78 (Ebit TTM -553.0m / Interest Expense TTM 63.0m)
EV/FCF = 14.21x (Enterprise Value 4.12b / FCF TTM 290.0m)
FCF Yield = 7.04% (FCF TTM 290.0m / Enterprise Value 4.12b)
FCF Margin = 16.06% (FCF TTM 290.0m / Revenue TTM 1.81b)
Net Margin = -38.26% (Net Income TTM -691.0m / Revenue TTM 1.81b)
Gross Margin = 28.68% ((Revenue TTM 1.81b - Cost of Revenue TTM 1.29b) / Revenue TTM)
Gross Margin QoQ = 20.73% (prev 33.26%)
Tobins Q-Ratio = 0.91 (Enterprise Value 4.12b / Total Assets 4.52b)
Interest Expense / Debt = 1.14% (Interest Expense 17.0m / Debt 1.49b)
Taxrate = 21.0% (US default 21%)
NOPAT = -436.9m (EBIT -553.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.15 (Total Current Assets 1.15b / Total Current Liabilities 366.0m)
Debt / Equity = 0.79 (Debt 1.49b / totalStockholderEquity, last quarter 1.88b)
Debt / EBITDA = -3.83 (negative EBITDA) (Net Debt 1.19b / EBITDA -309.0m)
Debt / FCF = 4.09 (Net Debt 1.19b / FCF TTM 290.0m)
Total Stockholder Equity = 2.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.17% (Net Income -691.0m / Total Assets 4.52b)
RoE = -33.65% (Net Income TTM -691.0m / Total Stockholder Equity 2.05b)
RoCE = -16.07% (EBIT -553.0m / Capital Employed (Equity 2.05b + L.T.Debt 1.39b))
RoIC = -12.69% (negative operating profit) (NOPAT -436.9m / Invested Capital 3.44b)
WACC = 6.90% (E(2.94b)/V(4.43b) * Re(9.94%) + D(1.49b)/V(4.43b) * Rd(1.14%) * (1-Tc(0.21)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.87%
[DCF Debug] Terminal Value 75.53% ; FCFF base≈203.2m ; Y1≈133.4m ; Y5≈60.9m
Fair Price DCF = 6.56 (EV 1.49b - Net Debt 1.19b = Equity 300.3m / Shares 45.8m; r=6.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -48.52 | EPS CAGR: -37.33% | SUE: 0.11 | # QB: 0
Revenue Correlation: -82.37 | Revenue CAGR: -11.25% | SUE: -1.39 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.99 | Chg30d=-0.126 | Revisions Net=+1 | Analysts=10
EPS current Year (2026-09-30): EPS=3.92 | Chg30d=-0.070 | Revisions Net=-2 | Growth EPS=+16.1% | Growth Revenue=+1.9%
EPS next Year (2027-09-30): EPS=4.75 | Chg30d=+0.038 | Revisions Net=-4 | Growth EPS=+21.0% | Growth Revenue=+3.7%